An Evaluation of Andexanet Alfa v. Standard of Care for Reversal of Doac-Induced Intracranial Hemorrhage - a Systematic Review and Meta-Analysis

Background Direct oral anticoagulants (DOACs) are reversible factor X inhibitors used to treat and prevent thrombotic complications such as venous thromboembolism and stroke in patients with atrial fibrillation. While offering benefits over traditional anticoagulants, they continue to present the risk of bleeding events, including intracranial hemorrhage (ICH). A recombinant form of factor Xa, Andexanet alfa, is available in some jurisdictions …